NCT04676828Recruiting
Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer
Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 15 Dec 2020
- Start date
- 1 Dec 2021
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- University of Aarhus
- Diseases
- Lung cancer
- NCT number
- NCT04676828
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 1 Dec 2021 to the primary completion date, 1 Dec 2027
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- concurrent immunotherapy
- previous radiotherapy to the thorax
Other illness
- other uncontrolled malignancies; any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
Who the study is looking for
- histologically verified lung cancer (small-cell and non-small cell lung cancer)
- referred for radiotherapy with curative intent
- radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and fractionation schedules accepted, as per site standard
- concurrent chemotherapy is accepted
- patients with oligometastatic disease are allowed, where metastasis have been ablated with surgery or radiotherapy
- receiving (chemo)-radiotherapy to the thoracic disease with curative intent
- adults over 18, that have given oral and written informed consent before patient registration.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sydney West Radiation Oncology Network Westmead and Blacktown Hospitals Coordinator of this site? Confirm its status | Sydney | Australia | Recruiting |
| Department of Oncology, Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.